news

CUPERTINO, Calif., Jan. 26 /PRNewswire-FirstCall/ — DURECT Corporation (Nasdaq: DRRX), an emerging specialty pharmaceutical company, announced today that it plans to expand its worldwide development program for its post-operative pain relief depot, SABER(TM)-Bupivacaine, by initiating additional Phase II studies for soft tissue and orthopedic surgical procedures. In addition, clinical studies will be conducted in the […]

CUPERTINO, Calif., Jan. 23 /PRNewswire-FirstCall/ — In conjunction with DURECT Corporation’s (Nasdaq: DRRX) fourth quarter and year-end 2005 financial results press release, you are invited to listen to its conference call that will be broadcast live over the Internet on Wednesday, February 8th, 2006 at 4:30 p.m. EST. (Logo: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO ) What: DURECT Corporation’s Fourth

CUPERTINO, Calif., Jan 06, 2006 /PRNewswire-FirstCall via COMTEX News Network/ — DURECT Corporation (Nasdaq: DRRX) announced today the appointment of four executives to its senior management team. Harry Guy has joined DURECT as Vice President of Engineering and Safety. In addition, DURECT announced today that Dr. Andrew R. Miksztal has been promoted to Vice President

CUPERTINO, Calif., Jan. 3 /PRNewswire-FirstCall/ — DURECT Corporation (Nasdaq: DRRX) announced today that it will present at the JPMorgan 24th Annual Healthcare Conference. The conference is being held at The Westin St. Francis Hotel in San Francisco. Dr. James E. Brown, President and Chief Executive Officer will be presenting at the conference on Monday January

CUPERTINO, Calif., Dec 26, 2005 /PRNewswire via COMTEX News Network/ — CUPERTINO, Calif., Dec. 26 /PRNewswire-FirstCall/–DURECT Corporation (Nasdaq: DRRX), an emerging specialty pharmaceuticals company, announced today positive preliminary results from a multiple dose clinical study in chronic pain patients for DURECT’s TRANSDUR(TM)-based sufentanil patch. (Logo: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO ) “The preliminary results of this Phase II clinical

CUPERTINO, Calif., Nov. 15 /PRNewswire-FirstCall/ — DURECT Corporation (Nasdaq: DRRX) announced today that the underwriters of its recent public offering of 7,400,000 shares of its common stock have exercised in full their over-allotment option to purchase an additional 1,110,000 shares of common stock, which includes 815,530 shares sold by DURECT and 294,470 shares sold by

CUPERTINO, Calif., Nov. 11 /PRNewswire-FirstCall/ — DURECT Corporation (Nasdaq: DRRX) announced the validation of the commercial potential of its ORADUR(TM) sustained release oral gel-cap technology with the recently announced strategic alliance to develop and commercialize Remoxy(TM), an ORADUR-based novel long-acting, abuse-deterrent oral formulation of oxycodone and other ORADUR-based products candidates using three other opioid drugs.

CUPERTINO, Calif., Nov. 4 /PRNewswire-FirstCall/ — DURECT Corporation (Nasdaq: DRRX) announced today that it will present at the Sixteenth Annual CIBC Healthcare Conference. The conference is being held at The Waldorf-Astoria Hotel in New York, New York. Dr. James E. Brown, President and Chief Executive Officer, will be presenting at the conference on Tuesday, November

CUPERTINO, Calif., Nov. 3 /PRNewswire-FirstCall/ — DURECT Corporation (Nasdaq: DRRX) announced today that it will present at the Rodman & Renshaw Techvest 7th Annual Healthcare Conference. The conference is being held at The Waldorf Astoria in New York, NY. Dr. James E. Brown, President and Chief Executive Officer, will be presenting at the conference on

CUPERTINO, Calif., Nov. 2 /PRNewswire-FirstCall/ — DURECT Corporation (Nasdaq: DRRX) announced today the pricing of its public offering of 7,400,000 shares of its common stock, including 32,256 shares of common stock offered by certain selling stockholders, at $5.00 per share. The Company and a selling stockholder have granted the underwriters a 30-day option to purchase